Cell Growth & Differentiation, Vol 8, Issue 12 1305-1316, Copyright © 1997 by American Association of Cancer Research

ARTICLES

Redundant functions of B-Myb and c-Myb in differentiating myeloid cells

J Golay, V Broccoli, GM Borleri, E Erba, M Faretta, L Basilico, GG Ying, G Piccinini, LH Shapiro, J Lovric, M Nawrath, K Molling, A Rambaldi and M Introna
Department of Immunology and Cell Biology, Istituto Ricerche Farmacologicalhe, Mario Negri, Milano, Italy.

We show in this report that the human myeloid leukemia cell line GFD8 is a useful model to compare the biological function of the structurally related c-Myb and B-Myb proto-oncogenes and to investigate the c-myb domains required for this function. GFD8 cells are dependent for growth on granulocyte-macrophage colony-stimulating factor and differentiate in response to phorbol myristate acetate (PMA). We have stably transfected this cell line with constructs constitutively expressing c-Myb or B-Myb. Deregulated expression of both c-Myb and B-Myb inhibited the differentiation observed in response to PMA and, in particular, the induction of the CD11b and CD11c antigens on the cell surface, and the induction of adherence. Furthermore, c-Myb and B-Myb enhanced expression of CD13 upon PMA treatment. Although deregulated Myb expression did not alter the growth factor dependence of the cells, it led to an increase in G2 relative to G1 arrest in cells induced to differentiate in response to PMA, whereas control vector-transfected cells were blocked mostly in G1. This decrease in G1 block took place despite normal induction of the cyclin-dependent kinase inhibitor protein p21 (CIP1/WAF1). Thus, GFD8 cells stably expressing the human B-Myb protein behaved in a manner indistinguishable from those stably expressing C-Myb for both differentiation and cell cycle parameters. In agreement with these findings and differently from most previous reports, transactivation assays show that B-myb can indeed act as a strong activator of transcription. Finally, we demonstrated that although the DNA-binding domain of c-myb is required for both the differentiation block and the shift in cell cycle after PMA treatment, phosphorylation by casein kinase II and mitogen-activated protein kinase at positions 11 and 12 or 532 of c-myb, respectively, are not. We conclude that c-Myb and B-Myb may activate a common cellular program in the GFD8 cell line involved in both differentiation and cell cycle control.

This article has been cited by other articles:

				M. Joaquin and R. J. Watson The Cell Cycle-regulated B-Myb Transcription Factor Overcomes Cyclin-dependent Kinase Inhibitory Activity of p57KIP2 by Interacting with Its Cyclin-binding Domain J. Biol. Chem., November 7, 2003; 278(45): 44255 - 44264. [Abstract] [Full Text] [PDF]

				M. A. Powzaniuk, R. Trotta, M. J. Loza, A. Harth, R. V. Iozzo, L. C. Eisenlohr, B. Perussia, and B. Calabretta B-Myb Overexpression Results in Activation and Increased Fas/Fas Ligand-Mediated Cytotoxicity of T and NK Cells J. Immunol., July 1, 2001; 167(1): 242 - 249. [Abstract] [Full Text] [PDF]

				P. G. Lutz, A. Houzel-Charavel, C. Moog-Lutz, and Y. E. Cayre Myeloblastin is an Myb target gene: mechanisms of regulation in myeloid leukemia cells growth-arrested by retinoic acid Blood, April 15, 2001; 97(8): 2449 - 2456. [Abstract] [Full Text] [PDF]

				G.-G. Ying, P. Proost, J. van Damme, M. Bruschi, M. Introna, and J. Golay Nucleolin, a Novel Partner for the Myb Transcription Factor Family That Regulates Their Activity J. Biol. Chem., February 11, 2000; 275(6): 4152 - 4158. [Abstract] [Full Text] [PDF]

				E. Grassilli, P. Salomoni, D. Perrotti, C. Franceschi, and B. Calabretta Resistance to Apoptosis in CTLL-2 Cells Overexpressing B-Myb Is Associated with B-Myb-dependent bcl-2 Induction Cancer Res., May 1, 1999; 59(10): 2451 - 2456. [Abstract] [Full Text] [PDF]